Arbor Emphasizes Risks Of Its Own Product In Suit Against US FDA To Block Nymalize Generics
Executive Summary
FDA concluded that original formulation of brain hemorrhage treatment was not discontinued for safety or effectiveness reasons, saying Arbor had other options to reduce risk of confusion between the new and original formulations. But the sponsor argues that withdrawal was part of FDA-approved risk mitigation plan.